ABL Bio (A298380) Stock Overview
A biotech research company, focuses on the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
A298380 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
ABL Bio Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩184,400.00 |
| 52 Week High | ₩257,500.00 |
| 52 Week Low | ₩31,300.00 |
| Beta | 0.50 |
| 1 Month Change | -6.63% |
| 3 Month Change | 8.53% |
| 1 Year Change | 293.18% |
| 3 Year Change | 767.76% |
| 5 Year Change | 810.62% |
| Change since IPO | 1,250.92% |
Recent News & Updates
Shareholder Returns
| A298380 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | -0.8% | 1.6% | 3.4% |
| 1Y | 293.2% | 42.6% | 100.6% |
Return vs Industry: A298380 exceeded the KR Biotechs industry which returned 44.8% over the past year.
Return vs Market: A298380 exceeded the KR Market which returned 103.6% over the past year.
Price Volatility
| A298380 volatility | |
|---|---|
| A298380 Average Weekly Movement | 12.2% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in KR Market | 13.1% |
| 10% least volatile stocks in KR Market | 2.9% |
Stable Share Price: A298380's share price has been volatile over the past 3 months compared to the KR market.
Volatility Over Time: A298380's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | n/a | Sang Hoon Lee | www.ablbio.com |
ABL Bio Inc., a biotech research company, focuses on the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases. The company offers ABL301, which is in the phase 1 clinical stage for the treatment of parkinson’s disease; ABL503 and ABL111 that is in phase 1 clinical stage for the treatment of solid tumor; and ABL102 for the treatment of solid and blood tumor. It also provides ABL103 for the treatment solid cancers; ABL104 for the treatment of solid tumor; and ABL105, which is in phase 1 clinical stage for the treatment of solid tumor.
ABL Bio Inc. Fundamentals Summary
| A298380 fundamental statistics | |
|---|---|
| Market cap | ₩10.20t |
| Earnings (TTM) | -₩28.65b |
| Revenue (TTM) | ₩88.44b |
Is A298380 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A298380 income statement (TTM) | |
|---|---|
| Revenue | ₩88.44b |
| Cost of Revenue | ₩58.80m |
| Gross Profit | ₩88.38b |
| Other Expenses | ₩117.02b |
| Earnings | -₩28.65b |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -518.02 |
| Gross Margin | 99.93% |
| Net Profit Margin | -32.39% |
| Debt/Equity Ratio | 23.6% |
How did A298380 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/17 21:41 |
| End of Day Share Price | 2026/02/13 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
ABL Bio Inc. is covered by 4 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jisoo Lee | DAOL Investment & Securities Co., Ltd. |
| Haesoon Kwon | Eugene Investment & Securities Co Ltd. |
| Hee Ryeong Jung | Kyobo Securities Co., Ltd |